Examkin

Question

Difficulty: Very hardNormal Pregnancy and Prenatal Care

During routine prenatal care, various screening tests and clinical evaluations are utilized to monitor maternal and fetal well-being. Match each specific clinical presentation or screening result with its most appropriate next step in management or physiological interpretation.

  • Ultrasound at 12 weeks gestation reveals a nuchal translucency of 3.8 mm; concurrent cell-free DNA testing indicates low risk for fetal aneuploidy.Recommend a targeted fetal anatomic survey and fetal echocardiography to rule out structural anomalies.
  • Maternal serum alpha-fetoprotein drawn at 16 weeks gestation returns markedly elevated at 2.9 multiples of the median.Perform a comprehensive obstetric ultrasound to evaluate for structural defects or incorrect pregnancy dating.
  • Midstream urine culture at 10 weeks gestation yields 10510^5 CFU/mL of Group B Streptococcus, successfully treated with appropriate antibiotics.Omit the standard third-trimester rectovaginal swab and mandate intrapartum intravenous antibiotic prophylaxis.
  • Laboratory evaluation at 9 weeks gestation demonstrates a suppressed TSH (0.2 mIU/L), elevated total T4, and normal free T4.Reassure the patient, as this reflects physiologic human chorionic gonadotropin-mediated stimulation and increased binding proteins.
  • Routine examination at 36 weeks gestation reveals a fundal height of 32 cm in a patient with a previously normal growth trajectory.Order an obstetric ultrasound to assess for suspected fetal growth restriction or oligohydramnios.

Answer

Pair each clinical scenario with its corresponding management: NT of 3.8mm with fetal echocardiography; elevated MSAFP with comprehensive ultrasound; GBS bacteriuria with omitting the third-trimester swab; suppressed TSH with reassurance for physiologic changes; and fundal height discrepancy with ultrasound for growth restriction.
Each presentation requires an understanding of advanced prenatal care guidelines: structural anomaly risks after normal aneuploidy screening, the workup of elevated MSAFP, lifelong/pregnancy indications for GBS prophylaxis, expected biochemical thyroid changes in pregnancy, and indications for fetal growth ultrasounds.

Step-by-Step Solution

1
Analyze the nuchal translucency and cell-free DNA results.
Identify that increased NT despite normal cfDNA carries a high risk of structural anomalies, primarily cardiac.
Cell-free DNA screens for aneuploidy but does not detect structural defects, requiring detailed fetal echocardiography.
2
Evaluate the elevated MSAFP result at 16 weeks.
Determine that ultrasound is required to visualize potential neural tube or ventral wall defects, or to correct gestational dating.
MSAFP is highly sensitive for open neural tube defects, but dating errors and multiple gestations are common causes of false positive results.
3
Assess the management of early pregnancy GBS bacteriuria.
Conclude that the patient is definitively colonized and requires intrapartum prophylaxis without further screening.
Any GBS bacteriuria during the current pregnancy bypasses the need for the standard late third-trimester culture.
4
Interpret the first-trimester thyroid panel.
Recognize the pattern of suppressed TSH, high total T4, and normal free T4 as a normal physiologic change.
hCG cross-reactivity and estrogen-induced thyroxine-binding globulin production perfectly explain these findings.
5
Evaluate the fundal height discrepancy.
Identify that a 4 cm lag in fundal height at 36 weeks is abnormal and requires investigation.
A size-dates discrepancy of greater than 3 cm necessitates an ultrasound to assess estimated fetal weight and amniotic fluid index.

Key Concept

Interpretation and management of routine prenatal screening and physiological adaptations
Rate this question

Topics

Normal Pregnancy and Prenatal Care

More questions from this topic